VERU Stock Summary and Trading Ideas (Veru | NASDAQ:VERU)

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

Veru trades on the NASDAQ stock market under the symbol VERU.

As of December 24, 2025, VERU stock price climbed to $2.34 with 97,331 million shares trading.

VERU has a beta of 0.50, meaning it tends to be less sensitive to market movements. VERU has a correlation of 0.01 to the broad based SPY ETF.

VERU has a market cap of $37.56 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, VERU traded as high as $65.70 and as low as $2.11.

The top ETF exchange traded funds that VERU belongs to (by Net Assets): VTI, VXF, MSSM.

VERU has underperformed the market in the last year with a price return of -63.8% while the SPY ETF gained +17.3%. VERU has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -30.6% and -11.0%, respectively, while the SPY returned +4.4% and +1.4%, respectively.

VERU support price is $2.21 and resistance is $2.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VERU shares will trade within this expected range on the day.